Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly/Daiichi Sankyo's prasugrel has carefully constructed label to control risk of bleeding - but it also includes a pharmacogenetic argument that Effient works in clopidogrel non-responders.
You may also be interested in...
Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations
The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.
Aggressive Antiplatelet Agents May Not Have Place In Low-Risk PCI Populations
The discontinuation of Lilly & Co./Daiichi Sankyo Ltd. Co.'s TRIGGER-PCI trial of Effient because of a low level of events in the patient population is consistent with the findings of the earlier GRAVITAS study of personalized therapy with Plavix, and may indicate that aggressive management isn't needed in lower risk patients after percutaneous coronary intervention.
Hospital Access, Reimbursement Slowing Effient Uptake, Execs Say
It wasn't long ago that Eli Lilly/Daiichi Sankyo's blood thinner Effient (prasugrel) was still considered an obvious blockbuster, kind of like a James Cameron movie. But now, six months post launch, Effient looks more like an art house film that might play well with a certain audience